Research and Development Overview

NeoPro Pain focuses on unique molecules derived from research that others are not doing and thus cannot be emulated. The company believes that this type of approach will generate unique drugs to treat neurological disorders such as acute and chronic pain. NeoPro Pain’s strategy is to complete the requirements for clinical trials for its candidate drug, EXIGAL™, and expand its pipeline through its research. EXIGAL™ is a unique new molecule for treatment of acute and chronic pain with the potential to replace many existing painkillers that have undesirable side effects.

Indication: Post-Surgery Pain
Stage: Late Preclinical